Scientific Programme

Monday, March 19, 2018

09.00                      Registration Opens

11.00                       Welcome Address
Heinz Zwierzina, Innsbruck, Austria

11.10 – 11.40           Impact of translational research on current immunotherapy trial programs
Ulrich Keilholz, Berlin, Germany

11.40 – 13.10          Opening – Plenary Symposium 1: Overcoming Immune Escape
Chair: Lisa Butterfield, Ulrich Keilholz

Tumor/Immune Cell Metabolism
Ping-Chih Ho, Lausanne, Switzerland

Current understanding of resistance to immunotherapy
Samir Khleif, Augusta, GA, USA

Novel genomic tools for cancer immunotherapy
Jacques Banchereau, Farmington, CT, USA

13.10 – 14.00        Lunch

14.00 – 15.00        Hot Topic Interactive Experts’ Session: Impact of the Microbiome in Immunotherapy
Chair: John Haanen, Samir Khleif

The impact of the microbiome on anti-tumor immunity and immunotherapy
Andreas Diefenbach, Berlin, Germany

15.00 – 15.50        Plenary Symposium 2: Emerging concepts / novel agents (1)
Chair: John Haanen, Samir Khleif

STING activation sequenced with immune checkpoint modulators overcomes immune tolerance
Leisha Emens, Baltimore, MD, USA

IDO inhibition in combination with checkpoint inhibition
Jason Luke, Chicago IL, USA

15.50 – 16.20        Coffee Break

16.20 – 18.20        Plenary Symposium 2: Emerging concepts / novel agents (2)
Chair: Sebastian Kobold, Paolo Ascierto

Combination of anti-LAG 3 antibodies with other checkpoint inhibitors
Paolo Ascierto, Naples, Italy

TLR and checkpoint inhibitor mediated immune modulation in tumor draining lymph nodes
Tanja de Gruijl, Amsterdam, Netherlands

Platelets, GARP and Cancer Immunotherapy
Zihai Li, Charleston, SC, USA

Immune landscape analysis to identify targets for immunotherapy across human carcinomas (A1)
J. Schnappinger
, Munich, Germany.   

Circulating regulatory T-cells and the clinical outcome of VEGF-targeted treatment of metastatic colorectal cancer patients: focused on KRAS status and primary tumour sidedness (A2)
L. Zdrazilova-Dubska, Brno, Czech Republic.

The use of EGFR-CD3 bispecific antibody and antigen-specific high avidity T cells to target cancer associated fibroblasts and cancer cells within a melanoma organoid system (A3)
N. Reddy, Duarte, CA, United States.

18.20                       Welcome Reception and Poster Viewing

Tuesday, March 20, 2018

08.30 – 09.30        Hot Topic Interactive Experts’ Session: Oncolytic Viruses
Chair: Eric Tartour, Leif Hakansson

Michael Bergmannn, Vienna, Austria

09.30-10.30            Plenary Symposium 3: Innate Immunity
Chair: Eric Tartour, Leif Hakansson

Reprogramming macrophages for tumour immunity
Michele de Palma, Lausanne, Switzerland

Next Generation Immunotherapies: NK Cells and Other Targets
Stéphanie Cornen, Marseille, France

PD-1 expression on innate lymphoid cells
Shoba Amarnath, Newcastle Upon Tyne, United Kingdom

10.30 – 11.00          Coffee Break

11.00 – 12.35         Plenary Symposium 4: Anti-cancer vaccines
Chair: Barbara Seliger, TBA

Tumor antigen-specific T cell epitopes – identification and clinical application
Stefan Eichmueller, Heidelberg, Germany

The role of neoantigen vaccination in the era of checkpoint inhibitors

Development of a DC vaccines and combinations
Lisa Butterfield, Pittsburgh, PA, USA

Combination therapy with anti-cancer vaccines and checkpoint Inhibitors
Lei Zheng, Baltimore, MD

The adjuvant effect of melanin is superior to Incomplete Freund adjuvant in a tumor subunit vaccine model (A4)
A.F. Carpentier, Paris, France

12.35 – 14.00          Lunch

14.00 – 15.00          Hot Topic Interactive Experts’ Session: Combinations to target immune excluded and immune desert solid Tumours
Introduction: NSCLC immune-phenotypes
Rudolf Maria Huber, Munich, Germany

3 brief presentations by the experts (8 minutes each):

  • Chemotherapy + checkpoint inhibitors: rationale and emerging data
    (Expert: Solange Peters, Lausanne, Switzerland)
  • Chemotherapy + antiangiogenesis agent + checkpoint inhibitor: rationale and emerging data
    (Expert: TBC)
  • Checkpoint inhibitor + T cell bispecific: rationale and emerging data
    (Expert: Ignacio Melero, Navarra, Spain)

15.00 – 15.45           Lifetime Achievement Award
CAR T cells in haematological malignancies: focused on the cure
Carl June, Philadelphia, PA, USA

15.45 – 16.15           Coffee Break

16.15 – 17.25          Plenary Symposium 5: Cell therapy
Chair: Zihai Li, Robert Hawkins

Adoptive T cell therapy of glioblastoma
Bryan Choi, Boston, MA, USA

Arming T cells with C-X-C Motive Receptor 6 as a universal approach for tumor directed T cell
Sebastian Kobold, Munich, Germany

T-cell Landscape Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines

17.25 – 18.25          Young researcher Session – Session 6
Chair: Leisha Emens, Sebastian Kobold

Omental fat in ovarian cancer induces metabolic and immune alterations (A5)
M. Suarez-Carmona, Heidelberg, Germany

GARP-TGFβ Axis on Activated Platelets Supports Tumor Progression (A6)
A. Metelli, Charleston, SC, United States

Preclinical characterization of a PD-1-CD28 fusion receptor in CD4+ T cells for T cell-based immunotherapy of pancreatic cancer and Non-Hodgkin Lymphoma (A7)
F. Rataj, München, Germany

Breast cancer immunotherapy using magnetised oncolytic viruses (A8)
H. AL-Janabi, Glasgow, United Kingdom

18.25                        Poster Viewing with Presenters

19.30                        ITOC5 Conference Dinner

Wednesday, March 21, 2018

08.30 – 10.05        Plenary Symposium 7: Monitoring of Immune response

Detection of tumour-infiltration immune cells by PET
Secondo Lastoria, Naples, Italy

Tissue biomarkers of response to Immunotherapy
Julien Adam, Villejuif, France

Tumor mutational burden as biomarker in NSCLC
Solange Peters, Lausanne, Switzerland

Circulating tumor DNA and response to immunotherapy

Determining tumor mutation load using an NGS-based, target gene panel (A9)
J. L. Costa, Porto, Portugal

Resident memory CD8+T cells as a biomarker of response to immunotherapy
Eric Tartour, Paris, Fance

10.25 – 11.00         Coffee Break

11.00 – 12.00         Plenary Symposium 7: Clinical Breakthrough with Immunotherapy
Joint Session with ESMO
Chair: Heinz Zwierzina, Christoph Zielinski

Adjuvant Therapy of Melanoma – Current Data and EORTC Perspective
Ulrich Keilholz, Berlin, Germany

Lung Cancer
Luis Paz-Ares, Madrid, Spain

Renal cell carcinoma

 12.00 – 12.30         Best Poster Awards & Closing Remarks

 12.30 – 13.30          Lunch


ITOC5 frames:

ITOC5 frames_Page_1